
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx is well-positioned for long-term growth, highlighted by its strong 2026 revenue guidance of $63M-$67M and expanding utilization of its Barostim therapy. The company's commercial model is also showing signs of improvement, with consistent productivity and plans to expand its sales territories. CVRx's recently announced BENEFIT-HF trial, which is supported by CMS and has the potential to significantly expand its TAM, further adds to the positive outlook on the stock. Ultimately, with a strong pipeline and positive market developments, CVRx has the potential to drive significant value for investors in the long run.
Bears say
CVRx is showing signs of continued strong financial performance, with revenue and gross margins exceeding expectations and center growth in line with estimates. Additionally, recent developments, including the first enrollment in the BENEFIT-HF trial and the Category I CPT code implementation, could expand the company's indicated TAM and improve commercial access for its Barostim product. These factors, along with the company's ongoing engagement with payers, suggest a potential for sustained growth in the future, but potential investors should closely monitor the impact of the ongoing salesforce disruption and potential delays in reimbursement processes.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares